Date: 2012-11-13
Type of information: Licensing agreement
Compound: EB66® cell line
Company: Vivalis (France) undisclosed partner
Therapeutic area: Cancer - Oncology
Type agreement: licensing
Action mechanism:
Disease:
Details: Vivalis has entered into a new EB66® cell line research agreement for the evaluation of two human anti-cancer vaccine candidates in the EB66® cell line. Terms of the agreement were not disclosed but do include fees for services performed by Vivalis.
Financial terms:
Latest news:
